The FLT3 gene is mutated in a significant proportion of high-risk pediatric ALL and AML; activating FLT3 mutations occur in 22% of AML and 18% of MLL-rearranged ALL. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.